Regulus Therapeutics Gets Funding

Carlsbad-based Regulus Therapeutics, a newly formed joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals, said Thursday evening that it has received funding to develop and commercialize microRNA therapeutics. The new joint venture combines intellectual property from Isis and Alnylam, and will be funded with an initial $10M investment by Alnylam. The new firm will is looking to develop new therapeutics based on microRNA (miRNA), which regulate networks of genes. More information »